Viracta Therapeutics Inc (VIRX)
$0.49
Live
Performance
- $0.48$0.50$0.49
2.04%
Downside
Day's Volatility :3.05%
Upside
1.03%
- $0.43$1.68$0.49
12.24%
Downside
52 Weeks Volatility :74.4%
Upside
70.83%
Returns
| Period | Viracta Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -41.37% | 6.5% | 0.0% |
6 Months | -10.09% | 7.1% | 0.0% |
1 Year | -66.51% | 9.8% | 0.0% |
3 Years | -95.52% | 14.2% | -20.2% |
Highlights
Market Capitalization | 19.6M |
Book Value | $0.14 |
Earnings Per Share (EPS) | -1.23 |
Wall Street Target Price | 5.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -51.49% |
Return On Equity TTM | -154.33% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -51.9M |
Diluted Eps TTM | -1.23 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.15 |
EPS Estimate Next Year | -0.98 |
EPS Estimate Current Quarter | -0.35 |
EPS Estimate Next Quarter | -0.31 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 920.41%
Technicals Summary
Sell
Neutral
Buy
Viracta Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Viracta Therapeutics Inc | -13.44% | -10.09% | -66.51% | -95.52% | -96.91% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Viracta Therapeutics Inc | 1.23 | NA | NA | -1.15 | -1.54 | -0.51 | NA | 0.14 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Viracta Therapeutics Inc | Buy | $19.6M | -96.91% | 1.23 | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Viracta Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 128.1%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 282.0%
Institutional Holdings
Bvf Inc
9.20%Vanguard Group Inc
2.96%Samsara BioCapital, LLC
1.76%LAURION CAPITAL MANAGEMENT LP
1.07%Mccormack Advisors International
0.93%BlackRock Inc
0.77%
Company Information
viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus, and will pursue opportunities to address other serious virus-associated disease.
Organization | Viracta Therapeutics Inc |
Employees | 40 |
CEO | Mr. Mark Andrew Rothera |
Industry | Healthcare |
